Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01497184 · ClinicalTrials.gov registry record · Phase 1
Infusion of Allogeneic CD19-Specific T Cells From Peripheral Blood
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 95
- Enrollment target
NCT01497184: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT01497184 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 95 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01497184, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 95 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if researchers can successfully and safely give HSCT patients an infusion of white blood cells (called T-cells) that have been genetically changed. The process of changing the DNA (the genetic material in cells) of these T-cells is called "gene transfer." Researchers want to learn if these genetically-changed T-cells are effective in attacking cancer cells in patients with advanced B-cell lymphoma or leukemia, after they have received standard allogeneic HSCT. Researchers want to find out the highest dose of these special T-cells that can be given safely to leukemia and lymphoma patients. Researchers also want to learn how long the changed T-cells stay in your body, and if adding them to standard transplant can improve how you respond to treatment.
Interventions
- PROCEDURE HSCT
- GENETIC DLI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2011-12 |
| Est. Completion | 2021-03-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01497184
The ClinicalTrials.gov registry entry for NCT01497184 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which HSCT is the first listed.
NCT01497184 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01497184 about?
NCT01497184 is a clinical study titled "Infusion of Allogeneic CD19-Specific T Cells From Peripheral Blood". The goal of this clinical research study is to learn if researchers can successfully and safely give HSCT patients an infusion of white blood cells (called T-cells) that have been genetically changed. The process of changing the DNA (the genetic material in cells) of these T-cells is called "gene tr...
What is the current status of trial NCT01497184?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 95 participants. The study started on 2011-12. Estimated completion is 2021-03-08.
What interventions are being tested in trial NCT01497184?
The interventions under investigation include: HSCT (PROCEDURE), DLI (GENETIC).
Who is sponsoring clinical trial NCT01497184?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.